Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
108147-54-2
Molecular formula
C6H13NO4
Molecular weight
163.17 g/mol
Drug class
Pharmacological chaperonealpha-galactosidase A stabiliser for Fabry disease
Mechanism of action
Reversibly binds the active site of amenable mutant alpha-galactosidase A (alpha-Gal A), stabilising the enzyme and promoting trafficking to lysosomes, where it can catabolise globotriaosylceramide and related substrates. It is only suitable for GLA variants demonstrated to be amenable to migalastat.
Indications / reported uses
Treatment of adults with a confirmed diagnosis of Fabry disease and an amenable GLA variant based on the validated in-vitro amenability assay; not indicated for non-amenable variants or paediatric patients
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Migalastat Environmental Risk Assessment (ERA) (the Migalastat ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.